👀 Ones to watch: The MOST undervalued shares to buy right nowSee Undervalued Shares

Dow Dips 200 Points; TJX Posts Upbeat Sales

Published 28/02/2024, 15:12
© Reuters.  Dow Dips 200 Points; TJX Posts Upbeat Sales
US500
-
DJI
-
TJX
-
GC
-
SI
-
IXIC
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday.

Following the market opening Wednesday, the Dow traded down 0.52% to 38,770.83 while the NASDAQ fell 0.63% to 15,933.71. The S&P 500 also fell, dropping, 0.33% to 5,061.21.

Check This Out: Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling

Leading and Lagging Sectors

Energy shares rose by 0.5% on Wednesday.

In trading on Wednesday, information technology shares fell by 0.8%.

Top Headline

The TJX Companies, Inc. (NYSE: TJX) posted better-than-expected sales for its fourth quarter on Wednesday.

TJX Companies posted GAAP earnings of $1.12 per share, in-line with market estimates. The company’s quarterly sales came in at $16.40 billion, versus expectations of $16.21 billion.

TJX said it sees FY25 earnings of $3.94 to $4.02 per share, versus estimates of $4.11 per share. The company expects consolidated comparable store sales gaining 2% to 3%.

Equities Trading UP

Vivani Medical, Inc. (NASDAQ: VANI) shares shot up 390% to $4.9478 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.

Shares of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) got a boost, surging 124% to $1.8969. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.

Bit Brother Limited (NASDAQ: BETS) shares were also up, gaining 63% to $4.0617.

Equities Trading DOWN

Oragenics, Inc. (NYSE: OGEN) shares dropped 45% to $1.35. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.

Shares of Integral Ad Science Holding Corp. (NASDAQ: IAS) were down 39% to $10.39 after the company reported fourth-quarter financial results.

Palatin Technologies, Inc. (NYSE: PTN) was down, falling 36% to $2.55 after the company reported results of PL9643 MELODY-1 pivotal Phase 3 clinical trial in patients with dry eye disease.

Also Check This Out: Top 3 Energy Stocks That Could Sink Your Portfolio In Q1

Commodities

In commodity news, oil traded up 0.8% to $79.53 while gold traded down 0.2% at $2,040.70.

Silver traded fell 0.8% to $22.575 on Wednesday while copper fell 0.7% to $3.8255.

Euro zone

European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.4%, London’s FTSE 100 fell 0.7% while Spain’s IBEX 35 Index fell 0.3% The German DAX gained 0.1% French CAC 40 fell 0.1% while Italy’s FTSE MIB Index declined 0.3%.

The services confidence indicator in the Eurozone fell to 6 in February, the lowest in three months, while economic sentiment indicator fell to 95.4 in February. The consumer confidence indicator in the Eurozone increased by 0.6 points to a reading of -15.5 in February.

Asia Pacific Markets

Asian markets closed lower on Wednesday, with Japan’s Nikkei 225 falling 0.08%, Hong Kong’s Hang Seng Index dipping 1.51%, China’s Shanghai Composite Index tumbling 1.91% and India’s S&P BSE Sensex falling 1.08%.

Hong Kong’s GDP increased by 4.3% year-over-year in the fourth quarter, up from a 4.1% increase in the prior period. The index of leading economic indicators in Japan was revised higher to 110.2 in December versus preliminary reading of 110, while index of coincident economic indicators was revised lower to 115.9 in December versus a flash reading of 116.2.

Economics

U.S. mortgage applications fell by 5.6% on the week ending Feb. 23.

The US economy grew an annualized 3.2% in the fourth quarter, versus a 4.9% rate in the previous quarter.

The U.S. trade deficit in goods rose to $90.20 billion in January versus a revised $87.89 billion in the prior month.

U.S. wholesale inventories declined by 0.1% month-over-month in January following a 0.4% increase a month ago.

Now Read This: Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.